Cancer is one of the leading causes of death worldwide, yet many types still don’t have regular screening programs. Even when screening is available, many people at higher risk find the tests difficult or uncomfortable to follow. Newer blood-based tests, like liquid biopsies, are showing promise for early detection of cancers. Liquid biopsy is a method where circulating tumor DNA (ctDNA) shed from the tumor is extracted and sequenced. This unveils the necessary information regarding cancer causing mutations in the related genes enhancing clinicians to decide the best course of treatment.
G2M offers a panel for liquid biopsy covering major cancer types like Lung, Breast and Colorectal cancer. This panel gives a detailed insight on cancer-related genes to uncover known as well as novel variants for further investigation.
Key features & highlights:
Early Answers for Lung Cancer Through Liquid Biopsy Liquid biopsy, powered by Next-Generation Sequencing (NGS), is revolutionizing how lung cancer is detected and managed. Unlike traditional tissue biopsies, which are often invasive and sometimes difficult to perform, liquid biopsy works by analyzing tiny fragments of tumor DNA (ctDNA) or tumor cells (CTCs) that are released into the bloodstream. This non-invasive approach allows clinicians to uncover critical genetic information about the tumor, making it possible to guide treatment and monitor disease with greater ease and precision.
| Features | Performance |
|---|---|
| Coverage uniformity (0.2X) | >99% |
| Reproducibility (%) | 96 |
| Sensitivity (%) | 96 |
| On Target Ratio (%) | 70-85 |
| Parameter | Description |
| Gene count | 32 |
| Covered region | Whole CDS |
| Target size | 110 Kb |
| Mutation types | SNV / InDels / CNV |
| Sample type | Blood / Plasma |
| Platform compatibility | Illumina, Thermo Fisher (Ion Torrent), MGI, Element Biosciences |
| Bioinformatics Support: | Primary Analysis: FASTQ to annotated VCF Secondary Analysis: CNVs, SNVs, InDel, Fusions Tertiary Analysis: Clinical interpretation |
| Type of Cancer | Gene | Drug |
|---|---|---|
| Non–small cell lung cancer (NSCLC) | ALK | Alectinib,crizotinib, ceritinib, lorlatinib, dabrafenib+trametinib |
| Non–small cell lung cancer (NSCLC) | BRAF | Dabrafenib+trametinib |
| Non–small cell lung cancer (NSCLC) | EGFR | Erlotinib, Osimertinib, gefitinib, erlotinib, afatinib, mobocertinib, amivantamb |
| Non–small cell lung cancer (NSCLC) | ERBB2 | Fam-trastuzumab deruxtecan-nxki |
| Commercial Name | Cat No. | Pack Size | Platform |
|---|---|---|---|
| ctDNA Lung NGS Test Kit | G710028-1 | 24 T | Illumina |
| G710028-2 | 96 T | Illumina | |
| G710028-3 | 96 T – EZY | Illumina – EZY | |
| ctDNA Lung NGS Test Kit | G710028-4 | 24 T | MGI |
| G710028-5 | 96 T | MGI | |
| G710028-6 | 96 T – EZY | MGI – EZY | |
| ctDNA Lung NGS Test Kit | G710028-7 | 24 T | Aviti |
| G710028-8 | 96 T | Aviti | |
| G710028-9 | 96 T – EZY | Aviti – EZY | |
| ctDNA Lung NGS Test Kit | G710028-10 | 24 T | Thermo |
| G710028-11 | 96 T | Thermo | |
| G710028-12 | 96 T – EZY | Thermo – EZY |
Download useful documents and technical information of Liquid Biopsy ctDNA Lung Cancer.
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
All products listed in the catalogue are the products of Genes2Me Private Limited. Apart from that, all other product names, trademarks and logos wherever used in the catalogue are the property of their respective owners.
© 2025 Genes2me. All rights reserved.
